SLC5A2 and acute kidney injury: This single-centre, open label, randomised, phase IV clinical trial included 55 patients and showed a significant reduction in AKI incidence of 46.7% (95% CI −69.7 to −23.6, p=0.001), comparing the use of an SGLT2 inhibitor (empagliflozin) with the untreated control group.17